ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.

Wang, Xueping; Wang, Fang; Zhong, Mengjun; Yarden, Yosef; Fu, Liwu*
Molecular Cancer2020-5-2DOI: 10.1186/s12943-020-01200-x
8阅读
引用收藏
分享

摘要

Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies (Abs) and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) Abs, are effective for patients with various cancers. However, low response rates to ICI monotherapies and even hyperprogressive disease (HPD) have limited the clinical application of ICIs. HPD is a novel pattern of progression, with an unexpected and fast progression in tumor volume and rate, poor survival of patients and early fatality. Considering the limitations of ICI due to HPD incidence, valid biomarkers are urgently needed to predict the occurrence of HPD and the efficacy of ICI. Here, we reviewed and summarized the known biomarkers of HPD, including tumor cell biomarkers, tumor microenvironment biomarkers, laboratory biomarkers and clinical indicators, which provide a potential effective approach for selecting patients sensitive to ICI cancer treatments.

学科与关键词

关键词
BiomarkerHyperprogressive diseaseImmunotherapyPD-1/PD-L1
相关
加载中…
  • Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer
    Chen, Shiyun; Gou, Miaomiao; Yan, Huan; Fan, Mengjiao; Pan, Yuting; Fan, Runjia; Qian, Niansong*; Dai, Guanghai*DISEASE MARKERS, 2021, 2021: 6639366.被引 13
  • Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
    Fan, Jingjing; Shen, Xiangfeng; Wang, Yishu; Zhou, Hong-Lan; Liu, Guolong; Li, Yu-Lin; Xu, Zhi-Xiang*Biomedicine and Pharmacotherapy, 2020, 130: 110621.被引 8
  • The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
    Tang, Qing; Chen, Yun; Li, Xiaojuan; Long, Shunqin; Shi, Yao; Yu, Yaya; Wu, Wanyin*; Han, Ling*; Wang, Sumei*Frontiers in Immunology, 2022, 13: 964442.被引 57
查看全部 →

发表信息

论文状态
公开发表
期刊
Molecular Cancer
发表日期
2020-05-02
卷期
第 19 卷, 第 1 期
页码
81
DOI
10.1186/s12943-020-01200-x
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
1区
成果收录
PUBMED

作者

  • W

    Wang, Xueping (第一作者)

  • W

    Wang, Fang

查看全部 5 位作者收起作者
  • Z

    Zhong, Mengjun

  • Y

    Yarden, Yosef

  • F

    Fu, Liwu (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417